Mario Rovirosa – CEO, Ferrer
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Founded in 1959, Ferrer is a Spanish multinational privately-held pharmaceutical company headquartered in Barcelona with a presence in over 90 countries. They operate in the pharmaceutical, health, fine chemicals (API), and food sectors. The company has expertise in the fields of cardiology, central nervous system, dermatology, gastroenterology, metabolism, oncology, musculoskeletal system, paediatrics, pain management, and respiratory.
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Alejandro Mora, Ferrer’s country manager for Central America & Caribbean, discusses the complexity of the region’s healthcare systems, the company’s strategy to compete against local players, and the importance for…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
CPH Pharma was the oldest running pharmaceutical company in Portugal until its acquisition by Grupo Ferrer in 2008. Since then, the company has continued to thrive in the marketplace despite…
Our business model is new in the Chilean market and enables us with great flexibility and allows us to focus on demand generation. For Ferrer this is a great window…
In the second part of a two-part interview, Generika Philippines co-founders, Teodoro Ferrer and Julien Bello, go on to discuss the future of generic medicines in the Philippines, the compnay’s…
In part one of a two-part interview, Generika Philippines co-founders Teodoro Ferrer and Julien Bello discuss what led them to start the company, the changing mentality among the Filipino population…
Javier Urzay, deputy director of Farmaindustria, the leading pharma industry association in Spain, discusses the main dynamics shaping the sector, including record levels of R&D investment and clinical trials, their…
Biogen’s managing director for Spain, Sergio Teixeira, reflects on the company’s key role in transforming multiple sclerosis and spinal muscular atrophy as examples of the American biotech giant commitment to…
Bial’s general manager for Spain and global director of its epilepsy franchise, Ana Álvarez, highlights the importance of the country for the organization – representing 25 percent of overall sales…
Soon after reaching its 60th anniversary, in 2015, the largest hospital in Catalonia and a group of sister institutions began working on the creation of a new type of campus.…
Dr Manel Juan is part of the team behind the development of the first European CAR-T-cell therapy to treat multiple myeloma, the second most common type of blood cancer. As…
Ángel Luis Rodríguez de la Cuerda, longtime secretary general of AESEG, the trade association of generic producers in Spain, comments on the key role played by generic medicines during the…
The president of the Business Federation of Spanish Pharmacists (FEFE), Luis Maria de Palacio Guerrero, reflects on the sector’s key contributions during the COVID-19 pandemic and explains why pharmacists must…
Merck’s general manager for Spain, Miguel Fernández Alcalde, speaks about the company’s shift towards becoming a global specialty innovator, what it means for their portfolio, and explains the group’s broad…
Madrid’s Minister of Health, Enrique Ruiz Escudero, explains in detail how the Autonomous Community executed a different COVID-19 strategy from other Spanish regions, following a “basic health zones” model, why…
CataloniaBio & HealthTech is an industry association representing the biomedicine and health sector in Catalonia. Its CEO, Judit Anido, explains how the region’s entrepreneurial spirit is helping it lead Spain…
Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19…
Lilly’s Nabil Daoud highlights the evolution in the firm’s Spanish manufacturing and R&D footprint in recent years, discussed launch plans for its next-generation diabetes and obesity treatments, and outlines some…
See our Cookie Privacy Policy Here
